Newron Pharmaceuticals SpA
SIX:NWRN

Watchlist Manager
Newron Pharmaceuticals SpA Logo
Newron Pharmaceuticals SpA
SIX:NWRN
Watchlist
Price: 7.86 CHF -2.12% Market Closed
Market Cap: 156.9m CHF

Wall Street
Price Targets

NWRN Price Targets Summary
Newron Pharmaceuticals SpA

Wall Street analysts forecast NWRN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NWRN is 16.76 CHF with a low forecast of 11.62 CHF and a high forecast of 26.25 CHF.

Lowest
Price Target
11.62 CHF
48% Upside
Average
Price Target
16.76 CHF
113% Upside
Highest
Price Target
26.25 CHF
234% Upside
Newron Pharmaceuticals SpA Competitors:
Price Targets
4568
Daiichi Sankyo Co Ltd
79% Upside
EYPT
EyePoint Pharmaceuticals Inc
449% Upside
4569
Kyorin Holdings Inc
5% Upside
REC
Recordati Industria Chimica e Farmaceutica SpA
14% Upside
GPCR
Structure Therapeutics Inc
219% Upside
AETHER
Aether Industries Ltd
45% Upside
CLN
Celon Pharma SA
15% Upside
603707
Nanjing King-friend Biochemical Pharmaceutical Co Ltd
81% Upside

Revenue
Forecast

Revenue Estimate
Newron Pharmaceuticals SpA

For the last 8 years the compound annual growth rate for Newron Pharmaceuticals SpA's revenue is 35%. The projected CAGR for the next 3 years is -27%.

35%
Past Growth
-27%
Estimated Growth
Estimates Accuracy
-3%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Newron Pharmaceuticals SpA

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-26%
Average Miss

Net Income
Forecast

Net Income Estimate
Newron Pharmaceuticals SpA

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-30%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is NWRN's stock price target?
Price Target
16.76 CHF

According to Wall Street analysts, the average 1-year price target for NWRN is 16.76 CHF with a low forecast of 11.62 CHF and a high forecast of 26.25 CHF.

What is Newron Pharmaceuticals SpA's Revenue forecast?
Projected CAGR
-27%

For the last 8 years the compound annual growth rate for Newron Pharmaceuticals SpA's revenue is 35%. The projected CAGR for the next 3 years is -27%.

Back to Top